Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Nanobiotix SA News

    5,40 € 0,00% +0,00 €
    08:00:58 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1J7EB
    ISIN: FR0011341205
    US-Symbol: NNBXF
    Typ: Aktie

    Nanobiotix SA News

    04.12.23 - GlobeNewswire
    Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
    Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent ...
    07.11.23 - GlobeNewswire
    NANOBIOTIX Announces Closing of Global Offering
    PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    06.11.23 - GlobeNewswire
    NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
    PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    02.11.23 - GlobeNewswire
    NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
    PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    01.11.23 - GlobeNewswire
    NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
    PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-​clinical stage ...
    09.07.19 - GlobeNewswire
    Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
    01.07.19 - GlobeNewswire
    Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
    04.06.19 - GlobeNewswire
    NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL
    28.05.19 - GlobeNewswire
    Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare
    04.04.19 - GlobeNewswire
    Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval
    02.04.19 - GlobeNewswire
    Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
    Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in ...
    26.03.19 - GlobeNewswire
    Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
    Moving forward with Overall Survival (OS)-based, randomized, event-​driven clinical trial for the United States Pre-IND feedback from US Food and Drug Administration (FDA) provides ...
    15.03.19 - GlobeNewswire
    Nanobiotix 2018 Annual Results
    Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “ Company ”), a clinical-​stage nanomedicine company ...
    04.03.19 - GlobeNewswire
    Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
    16.01.19 - GlobeNewswire
    Nanobiotix Plans to Conduct Registered Public Offering in the United States
    Nanobiotix Plans to Conduct Registered Public Offering in the United States Paris, France and Cambridge, Massachusetts (USA), January 16, 2019 – NANOBIOTIX SA (Euronext ...
    07.01.19 - GlobeNewswire
    Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
    Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-​in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, ...
    15.11.18 - GlobeNewswire
    Nanobiotix revenues for the 3rd quarter of 2018
    Paris, France and Cambridge, Massachusetts, USA, November 15, 2018 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-​stage nanomedicine company ...
    19.10.18 - GlobeNewswire
    NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
    16.10.18 - GlobeNewswire
    Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
    26.09.18 - GlobeNewswire
    Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences

    Newssuche

    Videos

    newspaper
    18.04.24 -3,65%
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »